Bockelmann v. Thermo Fisher Scientific: DNA Sequencing Patents Settled After 599 Days
Inventor Ulrich Bockelmann brought a patent infringement action against Thermo Fisher Scientific and Life Technologies, asserting two DNA sequencing patents against the Ion Torrent product family. The case ended after 599 days via a joint stipulated dismissal — plaintiff’s claims dismissed with prejudice, defendants’ counterclaims dismissed without prejudice — under a confidential private agreement.
An inventor’s sequencing patent claims reach a confidential resolution with Thermo Fisher
Filed on 24 November 2023 in the California Southern District Court, this infringement action pitted individual inventor Ulrich Bockelmann against Thermo Fisher Scientific and its subsidiary Life Technologies Corporation. Bockelmann asserted two patents — US7908088B2 and US7993825B2 — against a broad range of Ion Torrent sequencing instruments and consumables, including the Ion GeneStudio S5, Ion S5, Ion PGM, Ion Chef, Genexus systems, Ion 540 and Ion 530 chips, Ion Code Barcode Adaptors, and Ion Torrent CarrierSeq ECS Kits.
After 599 days, the parties filed a joint motion for voluntary stipulated dismissal on 15 July 2025. Bockelmann’s claims were dismissed with prejudice under Rule 41(a)(ii), meaning he cannot refile them. The defendants’ counterclaims, however, were dismissed without prejudice — leaving Thermo Fisher and Life Technologies with the theoretical ability to reassert those claims if circumstances change. The parties requested that the court retain jurisdiction to enforce the terms of their private agreement, a standard mechanism that suggests a structured settlement rather than a simple walk-away.
The 599-day timeline suggests the case progressed through at least early litigation phases before the parties negotiated terms. The retention-of-jurisdiction clause is commercially significant — it implies the agreement contains ongoing obligations (licensing royalties, product restrictions, or cross-licences) that may require judicial enforcement. The terms themselves remain confidential, so the economic value of any licence or payment is unknown from the public record. The without-prejudice dismissal of counterclaims is notable: it suggests Thermo Fisher preserved optionality on defences it may wish to deploy if future patent assertions arise from related IP.
Filing to Case Dismissed in 599 days
599 days in litigation — above median for two-patent district court infringement cases
Joint stipulated dismissal: what the asymmetric prejudice terms mean for both parties
Rule 41(a)(ii) stipulated dismissal with a retained-jurisdiction clause
A Rule 41(a)(ii) dismissal requires agreement of all parties and court approval. Here, plaintiff’s claims were dismissed with prejudice — a final adjudication on the merits for res judicata purposes — while defendants’ counterclaims were dismissed without prejudice, preserving their right to refile. The retained-jurisdiction request signals a structured settlement agreement with ongoing obligations, not a simple abandonment of the case.
Structured settlement likelyWith-prejudice dismissal: Bockelmann cannot refile these claims
Bockelmann’s infringement claims against Thermo Fisher and Life Technologies are permanently extinguished as to the conduct alleged. He cannot bring the same claims on US7908088B2 or US7993825B2 against the same products in a new action. In exchange, the parties presumably reached an agreement — terms undisclosed — that made this finality commercially acceptable. The court’s retained jurisdiction protects Bockelmann’s ability to enforce whatever was agreed.
Claims permanently resolvedCounterclaims preserved: defendants retain future flexibility
Thermo Fisher and Life Technologies secured dismissal without prejudice of their counterclaims, which typically include invalidity and non-infringement assertions. This asymmetry is strategically significant: if Bockelmann’s related patents or successors-in-interest assert similar claims in future, the defendants have not waived their defensive positions. The each-party-bears-own-costs clause suggests neither side sought to characterise the other as an exceptional case under 35 U.S.C. § 285.
Defensive posture preservedIon Torrent product line cleared — but agreement terms may carry licensing obligations
The retained-jurisdiction clause is the most commercially telling detail in the public record. Courts retain jurisdiction at parties’ request when there is a risk of future non-compliance — suggesting royalty payments, product use restrictions, or a cross-licence. For competitors and partners in the semiconductor-based DNA sequencing space, this case signals that the Bockelmann sequencing patents carry enough assertion value to warrant a negotiated resolution against a major platform player.
Likely licensing componentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ulrich Bockelmann | Individual | Individual inventor and patent holder — asserting DNA sequencing method patents US7908088B2 and US7993825B2Search in Eureka ↗ |
| Defendant | Thermo Fisher Scientific, Inc. | Company | Thermo Fisher Scientific and Life Technologies — global life sciences conglomerate, maker of Ion Torrent sequencing platformsSearch in Eureka ↗ |
| Co-Defendant | Life Technologies Corporation | Company | Search in Eureka ↗ |
| Co-Defendant | Does 1-10 | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Benjamin Charles Deming | Attorney | Counsel for Ulrich BockelmannSearch in Eureka ↗ |
| Plaintiff counsel | David Michael Newman | Attorney | Counsel for Ulrich BockelmannSearch in Eureka ↗ |
| Plaintiff counsel | Joseph J. Zito | Attorney | Counsel for Ulrich BockelmannSearch in Eureka ↗ |
| Plaintiff counsel | Kavon Adli | Attorney | Counsel for Ulrich BockelmannSearch in Eureka ↗ |
| Plaintiff law firm | Dnl Zito Castellano | Law Firm | Representing Ulrich BockelmannSearch in Eureka ↗ |
| Plaintiff law firm | The Internet Law Group | Law Firm | Representing Ulrich BockelmannSearch in Eureka ↗ |
| Defendant counsel | Helen Ji | Attorney | Counsel for Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Imron T. Aly | Attorney | Counsel for Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Jessica Bich Anh Do | Attorney | Counsel for Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Kevin Michael Nelson | Attorney | Counsel for Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Patrick Lai | Attorney | Counsel for Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Defendant law firm | ArentFox Schiff LLP | Law Firm | Representing Thermo Fisher Scientific, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text reveals an asymmetric dismissal architecture: plaintiff’s claims extinguished with prejudice while defendants’ counterclaims survive without prejudice. This structure is consistent with a negotiated resolution where the plaintiff accepted finality in exchange for agreed consideration, and the defendants preserved invalidity arguments as a hedge against future assertions from related patents. The retained-jurisdiction request is the clearest public signal that the settlement contains enforceable ongoing obligations — most commonly royalty payments or use restrictions.
US7908088B2 & US7993825B2 — DNA sequencing method patents at issue
US7908088B2 and US7993825B2 are method patents in the semiconductor-based DNA sequencing domain, filed under application numbers US10/538062 and US10/501772 respectively. Both patents relate to the technical foundation of ion-sensing next-generation sequencing — the approach commercialised in Thermo Fisher’s Ion Torrent platform, which detects hydrogen ions released during nucleotide incorporation rather than using optical fluorescence. Patents in this class sit at the intersection of semiconductor physics and molecular biology.
The Ion Torrent platform is one of the dominant non-optical sequencing architectures globally, embedded across clinical oncology, microbiology, and carrier screening workflows. Patents reading on the core ion-detection or signal-processing methods of this platform carry substantial assertion leverage: they potentially cover an entire instrument ecosystem rather than a single product. The breadth of accused products — from chips to full sequencing systems to barcode kits — is consistent with method claims that cover the sequencing workflow itself rather than a specific hardware component.
Should your sequencing platform be cleared against US7908088B2 and US7993825B2?
Any organisation developing, manufacturing, or commercialising semiconductor-based DNA sequencing instruments, chips, or workflow reagents should treat these patents as active assertion risks. The Bockelmann v. Thermo Fisher outcome — a structured settlement with retained jurisdiction — confirms that these patents have been validated as commercially serious by a major industry defendant. OEMs, kit manufacturers, and clinical laboratory developers working with ion-sensing sequencing architectures are directly in scope.
PatSnap Eureka’s FTO Search Agent enables rapid landscape clearance across US7908088B2, US7993825B2, and their cited and citing patent families. Eureka maps forward citations, identifies related continuations and divisionals, and surfaces co-assigned patents that may represent a broader assertion portfolio. For R&D teams designing next-generation sequencing consumables or instruments, Eureka’s claim-chart generation and prosecution history analysis can identify design-around pathways before product launch.
Run a freedom-to-operate analysis on US7908088B2 to assess your product’s exposure
Run FTO in Eureka →Similar DNA sequencing patent infringement cases in federal district courts
Cases involving semiconductor-based DNA sequencing method patents in the California Southern District and related federal courts, including Ion Torrent platform disputes.
What this case signals for the DNA sequencing IP landscape
A solo inventor extracting a structured settlement from a top-five life sciences company highlights the assertion risk embedded in foundational sequencing method patents.
Ion Torrent platform faces ongoing sequencing patent assertion risk
The breadth of products named — spanning chips, instruments, kits, and barcode adaptors — suggests Bockelmann’s patents read on core platform architecture, not peripheral features. Any company designing sequencing consumables or instruments in the Ion Torrent space should evaluate freedom-to-operate against US7908088B2 and US7993825B2 before commercialisation.
Retained jurisdiction signals structured deal, not walk-away
When parties request retained jurisdiction, it almost always means the settlement contains ongoing obligations. IP teams monitoring Thermo Fisher’s licensing cost structure should treat this as a likely royalty event. The without-prejudice counterclaim dismissal also suggests Thermo Fisher preserved invalidity arguments for potential future use against related patents in Bockelmann’s portfolio.
Bockelmann v Thermo — key questions answered
The case was dismissed by joint stipulation on 15 July 2025. Bockelmann’s infringement claims were dismissed with prejudice under Rule 41(a)(ii), meaning he cannot refile them. The defendants’ counterclaims were dismissed without prejudice. The parties entered a private agreement, and the court retained jurisdiction to enforce its terms. Each party bears its own costs.
Bockelmann asserted two patents: US7908088B2 (application no. US10/538062) and US7993825B2 (application no. US10/501772). Both relate to semiconductor-based DNA sequencing methods consistent with the ion-sensing technology underlying Thermo Fisher’s Ion Torrent platform.
The accused products included the Ion GeneStudio S5 systems, Ion S5 systems, Ion Torrent Personal Genome Machine (PGM), Ion Chef systems, Genexus systems, Ion 530 and Ion 540 chips, Ion Code Barcode Adaptors, Ion Torrent Ion CarrierSeq ECS Kits, and Ion Chips generally — spanning instruments, chips, and consumable workflow reagents.
When parties ask a court to retain jurisdiction to enforce a settlement agreement, it typically signals the agreement contains ongoing obligations — such as royalty payments, licensing milestones, or product-use restrictions — that one party might need to enforce if the other defaults. It is a strong indicator that the dismissal reflects a structured settlement rather than a simple abandonment of claims.
This asymmetric structure is common in patent settlements where the patent holder accepts finality in exchange for agreed consideration. The defendant retains the without-prejudice dismissal as a hedge: if related patents from the same inventor or portfolio are asserted in the future, the invalidity and non-infringement arguments preserved in the counterclaims can be refiled. It reflects Thermo Fisher preserving strategic optionality rather than fully closing all defences.
PatSnap Eureka searches patents and litigation data to answer instantly.